You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,879,327

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,879,327

Title:	Medicament for treating cancer
Abstract:	A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventor(s):	Noguchi; Toshihiro (Oklahoma City, OK), Baba; Akemi (Oklahoma City, OK), Hanada; Mitsuharu (Ibaraki, JP)
Assignee:	Dainippon Sumitomo Pharma Co., Ltd. (Osaka-Shi, JP)
Application Number:	11/761,264
Patent Claims:	1. A method of treating breast cancer, which is a breast cancer in which HER2 is highly expressed, comprising administrating an effective amount of trastuzumab and an effective amount of amrubicinol or a pharmaceutically acceptable salt thereof in combination, whereby said breast cancer is treated. 2. The method according to claim 1, comprising administering amrubicinol or a pharmaceutically acceptable salt thereof at 0.5-3.0 mg/kg/day while administering trastuzumab at 0.1-4.5 mg/kg/day. 3. The method according to claim 1, comprising administering amrubicinol or a pharmaceutically acceptable salt thereof on successive three days in every three weeks, while administering trastuzumab every one week. 4. The method according to claim 1, comprising administering amrubicinol or a pharmaceutically acceptable salt thereof at 1.5-9.0 mg/kg/day while administrating trastuzumab at 0.1-4.5 mg/kg/day. 5. The method according to claim 4, comprising administering amrubicinol or a pharmaceutically acceptable salt thereof on successive three days in every three weeks, while administering trastuzumab every one week. 6. The method according to any one of claims 1 to 5, wherein the dosage ratio of amrubicinol or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1-8:1 at one week after initiating the administration of both agents.

Details for Patent 7,879,327

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2020-07-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2020-07-28
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2020-07-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.